Recent Articles
Buy Hims & Hers Stock for a Solid Play on Telehealth
With its focus on millennials, fast growing telemedicine play HIMS stock has plenty of room to run after its recent SPAC merger.
Don’t Get Suckered Into Ocugen Stock
OCGN stock has gone crazy amid a partnership to develop a Covid-19 vaccine. The problem is there's little evidence it will actually work.
3 Reasons to Invite Opendoor Stock Into Your Portfolio
The underlying business of Opendoor stock brings convenience to the real estate market, and that alone is worth a premium.
Novavax’s Recent Consolidation Could Lead to More Gains
Novavax has been consolidating for months now. While doubts linger, NVAX stock could have serious upside if its Covid-19 vaccine works.
Pass on FuboTV Stock. There Are Better Options in Streaming.
FuboTV has made quite the splash, bringing out both bulls and bears who are defending their thesis. Let's skip past FUBO stock for now.
Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
